Aduro BioTech Inc. (ADRO)’s Financial Results Comparing With AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB)

Since Aduro BioTech Inc. (NASDAQ:ADRO) and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership of both companies.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aduro BioTech Inc. 16.09M 17.57 95.17M -1.17 0.00
AmpliPhi Biosciences Corporation N/A 395.60 10.14M -0.76 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Aduro BioTech Inc. and AmpliPhi Biosciences Corporation.


Table 2 demonstrates the return on assets, return on equity and net margins of Aduro BioTech Inc. and AmpliPhi Biosciences Corporation.

Net Margins Return on Equity Return on Assets
Aduro BioTech Inc. -591.49% -49.5% -23.3%
AmpliPhi Biosciences Corporation 0.00% -118.6% -84.7%

Volatility & Risk

A 2.34 beta means Aduro BioTech Inc.’s volatility is 134.00% more than Standard & Poor’s 500’s volatility. In other hand, AmpliPhi Biosciences Corporation has beta of 2.21 which is 121.00% more volatile than Standard & Poor’s 500.


Aduro BioTech Inc. has a Current Ratio of 9.3 and a Quick Ratio of 9.3. Competitively, AmpliPhi Biosciences Corporation’s Current Ratio is 2.1 and has 2.1 Quick Ratio. Aduro BioTech Inc.’s better ability to pay short and long-term obligations than AmpliPhi Biosciences Corporation.

Analyst Ratings

In next table is shown Aduro BioTech Inc. and AmpliPhi Biosciences Corporation’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aduro BioTech Inc. 0 0 1 3.00
AmpliPhi Biosciences Corporation 0 0 0 0.00

$10 is Aduro BioTech Inc.’s consensus target price while its potential upside is 180.90%.

Institutional and Insider Ownership

Roughly 49.1% of Aduro BioTech Inc. shares are owned by institutional investors while 5.7% of AmpliPhi Biosciences Corporation are owned by institutional investors. Aduro BioTech Inc.’s share owned by insiders are 1.3%. Comparatively, 1.28% are AmpliPhi Biosciences Corporation’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aduro BioTech Inc. 12.9% -34.12% -61.9% -57.89% -65.22% -62.67%
AmpliPhi Biosciences Corporation -21.59% -27.25% -78.61% -82.93% -79.24% -79.04%

For the past year Aduro BioTech Inc. was less bearish than AmpliPhi Biosciences Corporation.


On 6 of the 10 factors Aduro BioTech Inc. beats AmpliPhi Biosciences Corporation.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the companyÂ’s products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The company has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults. Its pipeline also includes AB-PA01 for the treatment of pseudomonas aeruginosa lung infections in cystic fibrosis and chronic rhinosinusitis patients. AmpliPhi Biosciences Corporation has a research collaboration agreement with Royal Brompton Hospital; a license agreement with University of Leicester to develop a phage therapy that targets and kills various clinically relevant toxin types of C. difficile; a cooperative research and development agreement with the U.S. Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research to develop and commercialize bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and a clinical trial agreement with the University of Adelaide. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.